<span item_type="fundamental" item_id="f3a5eda777fdd8fb2140e7b5661c3806" counter_id="ST/US/BIAFW" env="prod"></span><span item_type="announcement" item_id="549446824219250561" env="prod"></span><p>Revenue: As of FY2025 Q2, the actual value is USD 1.269 M.</p><p>EPS: As of FY2025 Q2, the actual value is USD -0.17.</p><p></p><h3>Segment Revenue</h3><ul><li>CyPath® Lung revenues increased 62% year-over-year for the six-month period ended June 30, 2025, reaching $323,000.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000164117225024036/ex99-1.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Revenue for the quarter ended June 30, 2025, was $1.3 million, compared with $2.4 million for the second quarter of 2024, due to the strategic decision to discontinue unprofitable pathology services.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000164117225024036/ex99-1.htm"></span></li><li>Operating expenses for the second quarter of 2025 were $3.8 million, down 16% from $4.5 million in the second quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000164117225024036/ex99-1.htm"></span></li><li>Net loss for the quarter ended June 30, 2025, was $4.1 million, or $0.17 per share, compared with a net loss of $2.1 million, or $0.19 per share, for the second quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000164117225024036/ex99-1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Cash and cash equivalents as of June 30, 2025, were $0.8 million, compared with $1.1 million as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000164117225024036/ex99-1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Completed a $3.25 million public offering in May 2025 providing working capital.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000164117225024036/ex99-1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>The company plans to expand access to CyPath® Lung, deliver operational efficiency, and advance the next generation of diagnostics and therapeutics.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000164117225024036/ex99-1.htm"></span></li><li>Strategic actions are aimed at reducing costs while expanding sales focus on high-margin diagnostics like CyPath® Lung.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000164117225024036/ex99-1.htm"></span></li><li>International patents are expected to expand CyPath® Lung’s global commercialization potential.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000164117225024036/ex99-1.htm"></span></li></ul>

BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM) | 8-K: FY2025 Q2 Revenue: USD 1.269 M